Introduction: Metformin tablets may be challenging to swallow not only for those patients with dysphagia but also for children and the elderly. A metformin solution was developed for easier administration and flexible dose adjustment mantained with the same bioavailability of tablets. The objective of this study was to assess the single-dose oral bioavailability of metformin hydrochloride administered as an oral solution (500 mg/5 mL) compared with
metformin hydrochloride 500 mg tablets in fasting Mexican healthy volunteers. Methods: A randomized, single dose, two-period, two-sequence, crossover study design with a 7-day washout interval was conducted. Subjects were randomly assigned to receive a single dose of 500 mg metformin hydrochloride, either as an oral solution (test drug) or as a tablet (reference drug), after 10 h of fasting. Plasma samples (16) were collected over a 16-h period after drug administration. Bioequivalence was declared when the ratio for the 90% confidence intervals (CI) of the difference in the means of the log-transformed area under the concentration-time curve from time 0 to the last observed concentration time (AUC 0-t ), the area under the concentration-time curve extrapolated to infinite time (AUC 0-? ), and the maximum plasma concentration (C max ) of the two products were within 0.80 and 1.25 interval. Plasma concentrations were analyzed using reverse phase chromatography by tandem mass spectrometry (LC-MS/MS). Safety and tolerability of metformin were also assessed in all subjects. Results: 24 subjects were enrolled and completed the study (15 female and 9 male). Test and reference metformin hydrochloride were bioequivalent during the extent of exposure since AUC 0-t and C max 90% CIs corresponded to 89.77-101.08% and 89.63-102.48%, respectively, both being within the pre-specified acceptance range criteria (80-125%). There were two adverse events (AE) with the reference formulation that were not related to the study drug. Conclusions: Bioequivalence in healthy volunteers in fasting conditions of the two metformin hydrochloride formulations (oral solution and tablets) was established, being the difference in means of AUC 0-t , AUC 0-? and C max within the acceptance range (80-125%). Oral solution formulation could offer the advantages of allowing adjusted doses and easier swallowing for every patient. Plain Language Summary: Plain language summary is available for this article. 
PLAIN LANGUAGE SUMMARY
Diabetes has become an increasing problem around the world, demanding new methods to reach and treat every type of patient. Metformin is the most common treatment for patients with diabetes mellitus type 2, and, since dose adjustment is usually made throughout the treatment, higher doses mean larger tablets which are associated with swallowing challenges in particular for younger and older patients. An oral solution of this drug may be useful to facilitate administration in these patients.
INTRODUCTION
Metformin [(N,N-dymethyl imidodicarbonimidic diamide) (C 4 H 11 N 5 = 129.2 g/mol); CAS-657-24-9] is an anti-hyperglucemic drug derived from biguanides. In addition to diet and exercise, it is used in adults as well as in pediatric patients for the treatment of type 2 diabetes. It decreases post-prandial hyperglycemia by increasing glucose uptake in skeletal muscle [1, 2] .
It is indicated as monotherapy in patients with type 2 diabetes. In patients with diabetes treated with sulfonylureas with a tendency to gain weight, metformin may be added to basal treatment or substituted by it [1] [2] [3] [4] . Metformin does not affect insulin secretion, but improves insulin resistance. It is used in combination with the exogenous insulin in patients with diabetes that do not respond to oral agents and thus require insulin administration. This combination facilitates a better glucemic control, reducing insulin requirements in pediatric patients older than 10 years as well as in adults [3] [4] [5] .
Its absorption takes place mainly in the small intestine, with a bioavailability of 50-60% and a half-life of about 3 h [1, 5] . It is not bound to plasmatic proteins and its volume of distribution is about 1.12 ± 0.08 L/kg. It is not metabolized and 90% of the oral dose is excreted in the urine as an active form [2] [3] [4] [5] [6] [7] [8] . The reference product is approved by Mexican Health Authorities (COFEPRIS, Ministry of Health, Mexico City) in pediatric patients older than 10 years of age as well as in adults [9] .
Metformin tablet size is directly related to the strength, therefore 850 mg and 1000 mg tablets' size become a challenge for certain patients, not only those with dysphagia, which may be more common in children and older people; in these groups of patients, therapeutic adherence may be affected. Usual practice for adjusting doses include crushing a tablet, opening the capsule or chewing the tablets, thus increasing the risk of sub-therapeutic doses, administration problems and the uncertainty of a well-established bioavailability. Therefore, many patients may benefit from an other pharmaceutical form that allows a simpler management of fractioned doses to lower the risk of adverse events and ensure a better control of patients [10, 11] .
The objective was to compare the bioavailability between two different oral formulations of metformin (oral solution 500 mg/5 mL and oral tablets 500 mg) in healthy, Mexican volunteers.
METHODS

Subject Selection
Mexican healthy adult volunteers of either gender, 18-55 years old, with a body mass index between 18.0-27.0 kg/m 2 , were enrolled in the study. All subjects were in good physical health, as assessed through full physical examination, electrocardiogram (ECG) recording, vital signs measurement and clinical laboratory assays (hematology, blood chemistry, urinalysis, HIV, hepatitis B and C serology), according to the study inclusion criteria. Exclusion criteria included a history or presence of significant diseases, no antecedents of hypersensitivity to metformin or any other drug, negative to HIV, hepatitis B and C, history of alcohol and drug abuse, ingested 24 h previous to the study any food containing xanthines, alcohol, carbonated beverage, orange or grapefruit, any medication for 7 days prior to the start of the study, subjects hospitalized for any problem during the 3 months prior to the start of the study, donated or lost 450 mL blood in the past 60 days, and in the case of women, positive pregnancy test. Subjects were not enrolled if they had participated in other clinical trials in the last 3 months.
Study Design
This study was conducted in accordance with the principles of the Declaration of Helsinki and its amendments [11] , the International Conference on Harmonization Guideline for Good Clinical Practice [12] , Guidance for Industry, Bioavailability and bioequivalence studies submitted in NDAs or INDs (FDA) [13] , administration's in vivo bioequivalence guidances [14] , Guideline on the Investigation of Bioequivalence (EMA) [15] and Mexican bioequivalence guideline [16] . The study protocol and the informed-consent form were approved by the ethics and research committee of the University Hospital ''Dr. Jose E. Gonzalez'' Universidad Autonoma de Nuevo Leon (U.A.N.L.) and by the Mexican Health Authorities (COFEPRIS, Ministry of Health, Mexico City).
This study was single-center, single-dose, open-label, randomized sequence, two-way and cross-over. The test formulation was a metformin hydrochloride oral solution (Laboratorios Silanes; 500 mg/5 mL) and the reference was tablets (Dabex Ò , Laboratorios Merck; 500 mg). Both products were orally administered in two study periods, randomly assigned to receive either the test or reference formulations, with a wash-out interval of 7 days between administrations.
The study randomization list was computergenerated by the Clinical Unit of Pharmacology and Toxicology Department of Universidad Autonoma de Nuevo Leon, Mexico. Subjects were confined at the clinical center from the evening before administration until 16 h post-dose; they were in fasting conditions for 10 h before administration and up to 4 h post-dose. Water was allowed ad libitum, except for 1 h before and 2 h after dosing. In both study periods, the test formulation was administered on day 1 at 06:00 hours and under fasting conditions.
For the test formulation, 5 mL were placed in a dosing syringe and given to each subject to place the solution in the oral cavity before ingestion of 250 mL of water. For the reference formulation, the tablet was swallowed with 250 mL of water.
Determination of Plasma Metformin Concentrations
Blood samples for metformin hydrochloride measurements were collected at pre-dose (0) and 15 and 30 min and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12 and 16 h post-dose. Sampling time points were selected based on previous reports [3] [4] [5] [6] [7] [8] . Blood samples were collected using a peripheral venous catheter. The first 1 mL of blood was discarded at each collection time to avoid contamination of the sample with heparin. Then, 4.5 mL of blood was drawn in each sample point with a vacutainer glass tube containing sodium citrate as an anticoagulant. The samples were centrifuged immediately at 3000 rpm for 10 min at 5°C. The plasma obtained was transferred after being appropriately labeled into a 2-mL polypropylene cryotube, which was stored frozen at -70°C until their analysis.
Concentrations of metformin hydrochloride in the plasma were determined with the method previously reported by Montoya-Eguía et al. [17] , and validated according to the requirements of the Mexican bioequivalence guideline [15] which is based on the FDA and EMA guidelines [13] [14] [15] [16] .
The method had a lower limit of quantification (LQL) of 39.45 ng/mL and adhered to the regulatory requirements for selectivity, sensitivity, precision, accuracy, recovery, carry-over, matrix effect, and stability.
Samples for determining metformin concentration were processed by precipitating proteins with acetonotrile. They were analyzed using reverse phase chromatography by tandem mass spectrometry. Analytical runs were carried out to determine that each metformin concentration fulfilled requirements according to the acceptance criteria and corresponding evaluation [17, 18] .
Pharmacokinetic Parameters and Statistical Analyzes
Pharmacokinetic parameters were determined or calculated using the validated software WinNonlin Ò 6.03 (Pharsight) [19] . Plasma metformin hydrochloride, maximum plasma concentration (C max ) and area under the concentration-time curve from time 0 to the last observed concentration time (AUC 0-t ) and extrapolated to infinite time (AUC 0-? ) were calculated using the linear trapezoidal rule. The primary end-point of the study was the comparison of bioavailability of the two formulations, considering C max , AUC 0-t and AUC 0-? .
The following pharmacokinetic parameters were also calculated: constant elimination rate (K e ), mean residence time (MRT), time to achieve maximum plasma concentration (T max ), and terminal half-life (t 1/2 ).
The sample size was based on the intra-subject variability for C max (23.6%) obtained in a previous phase I study with healthy subjects [3] [4] [5] [6] [7] [8] . The following assumptions were made for sample size calculations: significance level of 5%, 80% of power, intra-subject CV of 23.6%, and equivalence limits between 80 and 125%.
Based on these assumptions, 20 evaluable subjects were needed for the bioequivalence assessment. In order to prevent a loss in sample size calculations due to drop-outs or major protocol violations, four extra subjects were included, resulting in a total of 24 subjects.
A classical bioequivalence test was used for the comparison of metformin hydrochloride (test and reference) pharmacokinetic parameters. Log-transformed C max , AUC 0-t and AUC 0-? were analyzed by variance analysis, with treatment, period, sequence and subject-within-sequence as fixed effects. Similarity criterion was a geometric means ratio (PE) around 100% and its 90% confidence interval (CI) within the range 80-125% [13] [14] [15] [16] .
Descriptive statistical analysis was performed for demographic variables such as age, weight, height, body mass index and pharmacokinetic data obtained.
Safety
The safety profile was assessed by evaluating treatment-emergent adverse events (AEs), physical examination, ECG, laboratory tests and monitoring of vital signs.
Vital signs (blood pressure, heart rate, respiratory rate and body temperature) were measured at screening, on day 1 of each study period at pre-dose (morning), post-dose (evening) and final visit.
A 12-lead resting ECG was recorded at the screening visit. Blood and urine samples were collected for routine hematology, blood chemistry, urinalysis, HIV, and hepatitis B and C serology at the screening visit. AEs were planned to be assessed throughout the study. A full physical examination was performed by the investigator at screening and at the final visit.
RESULTS
A total of 24 subjects were enrolled and completed the study. No abnormalities were found in clinical or biochemical parameters when comparing baseline versus end of study evaluations. There was no use of concomitant drugs by any subject.
Subjects received the study treatment by the allocated formulation sequence. Demographic characteristics of the analyzed subjects are presented in Table 1 . Table 2 shows the 90% CI of the ratios (test/ reference) for log-transformed C max , AUC 0-t and AUC 0-? and the probability of exceeding the limits of acceptance (Schuirmann's two onesided t tests, and the power of the test). Figure 1 shows plasma concentration time profiles.
Pharmacokinetic Parameters
Maximum plasma concentration (C max ) of metformin hydrochloride was 1158.0 ± 332.01 ng/mL for the oral solution (test formulation) and 1215.0 ± 376.53 ng/mL for the tablet (reference formulation). AUC 0-t values were 6795.5 ± 1840.74 hÁng/mL for the test formulation and 7133.1 ± 2002.87 hÁng/mL for the reference. AUC 0-? values were 7037.8 ± 1829.01 and 7397.4 ± 2024.80 hÁng/mL for the test and reference formulations, respectively.
The ratios of the test/reference geometric means (point estimate, PE %) were nearly 100% for C max , AUC 0-t and AUC 0-? , with their corresponding 90% CI within the pre-specified acceptance limits of (80-125%).
Safety
There were two adverse events in the tablet group which were not related to the medication: one subject had a fall with incomplete fracture of clavicle during the washout period, the other one was diagnosed with an upper respiratory tract infection; both were followed until clinical resolution.
DISCUSSION
It is important for prescribers and other healthcare professionals to assess if patients have swallowing difficulties that may affect adherence, efficacy or tolerability. An oral formulation should be well tolerated, effective, stable and have an acceptable flavor; these characteristics may warrantee a successful treatment (solid formulations might cause treatment abandonment), particularly in younger and older patients, those patients with dysphagia or special physiological conditions, or even personal preference against taking certain medicines for whom larger solid-dose formulations represent a swallowing challenge. Oral solution formulation offers the advantage of allowing lower doses and precise dose adjustment with uniformity of content [9, 10] .
Mean metformin hydrochloride plasma concentration-time profiles up to 16 h after single-dose oral solution and tablet administration were similar in their rate and extent of absorption in both products. The ratio of test/ reference geometric means was very close to 100% for C max , AUC 0-t and AUC 0-? , indicating a comparable extent of exposure with the two formulations. The 90% CI were within the equivalence limits of 80-125% for these pharmacokinetic parameters.
The similarity in t 1/2 , elimination rate constant and mean residence time values obtained in this study confirmed that the oral solution and tablet presented similar elimination kinetics after dosing. A comparison of the present results with the literature data [3] [4] [5] [6] [7] [8] 17] showed similar rates and extents of absorption.
Safety data confirmed a favorable safety profile of the investigational product, administered as single oral dose by both the oral solution and tablet.
Since the objective of the study was to compare the relative bioavailability of two different formulations (tablet vs. solution) the study was carried out under fasting conditions taking into account that food could modify the release of the drug substance of a drug product into the systemic circulation.
As with any clinical trial, the current study had limitations that should be considered. Since data were obtained only from healthy subjects who received a single dose, the pharmacokinetic characteristic of metformin might differ in target populations. As the study was carried out under fasting conditions, we are unable to predict the metformin pharmacokinetic profile under fed conditions.
CONCLUSIONS
Study data show that 500 mg/5 mL of the test product is equivalent to 500 mg of the reference product of metformin hydrochloride in healthy subjects in fasting conditions. Oral solution formulation is an available alternative regarding swallowing problems. It allows a simpler and safer dose adjustment for younger and older patients with: dysphagia, special physiological conditions or with personal preference for non-solid dose formulations, in whom it might be the difference between success and therapeutic failure by improving treatment adherence specifically for diabetes mellitus type 2.
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